A-Alpha Bio
PrivateLast Round
Grant
May 21, 2024
Total Funding Raised
$65.1M
Company Overview
A-Alpha Bio is a biotechnology company that combines synthetic biology and machine learning to analyze protein-protein interactions for drug discovery and development. The company was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design. A-Alpha Bio has two main platforms: AlphaSeq, which experimentally measures millions of protein-protein interactions simultaneously, and AlphaBind, a machine learning platform trained on this data to predict binding from protein sequences. The company leverages these platforms for its internal oncology-focused therapeutic pipeline and through partnerships with major pharmaceutical companies like Bristol Myers Squibb and Gilead Sciences. As of July 2023, A-Alpha Bio had raised a total of $51 million in funding.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, ML Platforms, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
A-Alpha Bio Comps
Public and private peers based on sector, stage, and business model.
A-Alpha Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 21, 2024 | ||||
| Series A Extension | Jul 25, 2023 | ||||
| Grant | May 16, 2023 | ||||
| Grant | Mar 1, 2022 | ||||
| Series A | Sep 8, 2021 | ||||
Grant | Sep 1, 2020 |
Key People
Founding team and executive leadership
A-Alpha Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boom Capital | Seed |
| Perceptive Xontogeny Ventures | Series A Extension |
| Lux Capital | Series A |
| Perceptive Xontogeny Venture Fund | Series A |
| Breakout Ventures | Series A Extension |
| Washington Research Foundation Capital | Seed |
| Canaan Partners | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 3, 2026
Partnered with Novo Nordisk to enhance drug discovery using its AI platform.
- Sep 23, 2025
Troy Lionberger appointed to drive next phase of growth.
A-Alpha Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about A-Alpha Bio's valuation, stock price, and market status.
